0.4378
price down icon0.82%   -0.0036
pre-market  Pre-mercato:  .43   -0.0078   -1.78%
loading
Precedente Chiudi:
$0.4414
Aprire:
$0.4314
Volume 24 ore:
417.75K
Relative Volume:
0.32
Capitalizzazione di mercato:
$22.53M
Reddito:
-
Utile/perdita netta:
$-22.83M
Rapporto P/E:
-0.5542
EPS:
-0.79
Flusso di cassa netto:
$-20.87M
1 W Prestazione:
+17.56%
1M Prestazione:
-4.68%
6M Prestazione:
-22.50%
1 anno Prestazione:
-77.32%
Intervallo 1D:
Value
$0.4203
$0.4408
Intervallo di 1 settimana:
Value
$0.353
$0.4499
Portata 52W:
Value
$0.3051
$2.95

Cognition Therapeutics Inc Stock (CGTX) Company Profile

Name
Nome
Cognition Therapeutics Inc
Name
Telefono
412-481-2210
Name
Indirizzo
2403 SIDNEY STREET, PITTSBURGH
Name
Dipendente
25
Name
Cinguettio
Name
Prossima data di guadagno
2024-08-08
Name
Ultimi documenti SEC
Name
CGTX's Discussions on Twitter

Confronta CGTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CGTX
Cognition Therapeutics Inc
0.4378 22.53M 0 -22.83M -20.87M -0.79
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-19 Aggiornamento B. Riley Securities Neutral → Buy
2024-07-30 Downgrade Cantor Fitzgerald Overweight → Neutral
2021-11-03 Iniziato B. Riley Securities Buy
2021-11-03 Iniziato Oppenheimer Outperform

Cognition Therapeutics Inc Borsa (CGTX) Ultime notizie

pulisher
02:40 AM

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Analysts - Defense World

02:40 AM
pulisher
Apr 25, 2025

Cognition Therapeutics Inc [CGTX] Shares Fall Approximately -76.27% Over the Year - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

Cognition Therapeutics Inc (CGTX) Stock: Navigating a Year of Volatility - investchronicle.com

Apr 25, 2025
pulisher
Apr 09, 2025

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2024 Earnings Call Transcript - MSN

Apr 09, 2025
pulisher
Apr 08, 2025

Tscan Therapeutics Inc (TCRX) deserves deeper analysis - uspostnews.com

Apr 08, 2025
pulisher
Apr 08, 2025

2025 Is Shaping Up To Be A Big Year For This Drug Maker Working To Cure Dementia - Benzinga

Apr 08, 2025
pulisher
Apr 03, 2025

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of “Buy” by Analysts - Defense World

Apr 03, 2025
pulisher
Apr 01, 2025

Cognition Therapeutics reports promising Alzheimer’s study results By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Cognition Therapeutics reports promising Alzheimer’s study results - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Cognition Therapeutics Presents Results at AD/PD 2025 - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

Breakthrough: Cognition's Alzheimer's Drug Reduces Multiple Disease Markers in Phase 2 Trial - Stock Titan

Apr 01, 2025
pulisher
Mar 28, 2025

Equities Analysts Set Expectations for CGTX FY2025 Earnings - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Contrasting Alpha Cognition (NASDAQ:ACOG) & Cognition Therapeutics (NASDAQ:CGTX) - Defense World

Mar 27, 2025
pulisher
Mar 27, 2025

HC Wainwright Has Bearish Estimate for CGTX Q1 Earnings - Defense World

Mar 27, 2025
pulisher
Mar 26, 2025

Dementia Associated With Alzheimer’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Mar 26, 2025
pulisher
Mar 26, 2025

What is HC Wainwright’s Forecast for CGTX Q1 Earnings? - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

Cognition Therapeutics to Report Biomarker Results from - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Cognition Therapeutics to present Alzheimer’s study results By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

Agitation in Alzheimer's Disease Market: Analysis - openPR.com

Mar 25, 2025
pulisher
Mar 25, 2025

Cognition to Reveal Biomarker Findings Next Week - Baystreet.ca

Mar 25, 2025
pulisher
Mar 25, 2025

Cognition Therapeutics to present Alzheimer’s study results - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025 - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Cognition Therapeutics to Present Phase 2 SHINE Study Biomarker Results for Zervimesine at AD/PD 2025 Conference - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

Game-Changing Alzheimer's Treatment: New Phase 2 Data Reveals Multiple Positive Biomarkers - Stock Titan

Mar 25, 2025
pulisher
Mar 25, 2025

Cognition Therapeutics (NASDAQ:CGTX) Price Target Cut to $5.00 by Analysts at HC Wainwright - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Cognition Therapeutics stock price target cut to $5 at H.C. Wainwright - Investing.com Canada

Mar 24, 2025
pulisher
Mar 23, 2025

Cognition Therapeutics Earnings Call: Progress Amid Challenges - MSN

Mar 23, 2025
pulisher
Mar 23, 2025

Chardan Capital Has Lowered Expectations for Cognition Therapeutics (NASDAQ:CGTX) Stock Price - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Brookline Capital lifts Cognition Therapeutics stock to $7 target By Investing.com - Investing.com Canada

Mar 21, 2025
pulisher
Mar 21, 2025

Cognition Therapeutics Inc (CGTX) Q4 2024 Earnings Call Highlights: Strategic Focus on ... By GuruFocus - Investing.com Canada

Mar 21, 2025
pulisher
Mar 21, 2025

New Horizons in Lewy Body Dementia Market Exploring Future - openPR.com

Mar 21, 2025
pulisher
Mar 21, 2025

Cognition Therapeutics: Navigating the Complexities of Alzheimer's and DLB Trials - AInvest

Mar 21, 2025
pulisher
Mar 21, 2025

Cognition Therapeutics Advances Alzheimer’s and DLB Trials - TipRanks

Mar 21, 2025
pulisher
Mar 20, 2025

Earnings call transcript: Cognition Therapeutics Q4 2024 sees $34M net loss - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

Cognition Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

COGNITION THERAPEUTICS Earnings Results: $CGTX Reports Quarterly Earnings - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

COGNITION THERAPEUTICS INC SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Cognition Therapeutics, Inc. Reports Positive Phase 2 Results for Zervimesine in Dementia with Lewy Bodies and Alzheimer's Disease, Plans Advancement to Late-Stage Trials - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 20, 2025
pulisher
Mar 19, 2025

Lewy Body Dementia Market to Show Remarkable Growth Trends from - openPR

Mar 19, 2025
pulisher
Mar 18, 2025

Alzheimer's disease Clinical and Non-Clinical Studies, Key - openPR

Mar 18, 2025
pulisher
Mar 18, 2025

Cognition Therapeutics (CGTX) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 18, 2025
pulisher
Mar 13, 2025

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results - The Manila Times

Mar 13, 2025
pulisher
Mar 13, 2025

Cognition Therapeutics Q4 Earnings: Key Date Revealed for Crucial Neurodegenerative Treatment Updates - StockTitan

Mar 13, 2025
pulisher
Mar 13, 2025

Cognition Therapeutics at Life Sciences Forum: Progress in Alzheimer’s and Lewy Body Dementia - Investing.com UK

Mar 13, 2025
pulisher
Mar 13, 2025

Cognition Therapeutics shifts to Nasdaq Capital Market By Investing.com - Investing.com India

Mar 13, 2025
pulisher
Mar 12, 2025

Cognition Therapeutics, Inc. Transitions to Nasdaq Capital Market Following Compliance Notification - Nasdaq

Mar 12, 2025

Cognition Therapeutics Inc Azioni (CGTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Capitalizzazione:     |  Volume (24 ore):